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OBJECTIVES We hypothesized that impaired renal function would also be associated with poorer clinical
outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated
with fibrinolysis.
BACKGROUND Previous studies have demonstrated that impaired renal function is associated with poorer
clinical outcomes in the setting of unstable angina and non-STEMI and after percutaneous
coronary intervention.
METHODS Data were drawn from the Thrombolysis In Myocardial Infarction (TIMI)-10, TIMI-14,
and Intravenous nPA for the Treatment of Infarcting Myocardium Early (InTIME-II) trials.
RESULTS Within each TIMI risk score (TRS) for STEMI category (0 to 2, 3 to 4, 5), 30-day
mortality increased stepwise among patients with normal (creatinine [Cr] 1.2 mg/dl),
mildly (Cr 1.2 to 2 mg/dl), and severely (Cr 2.0 mg/dl) impaired renal function (p 
0.001) and in patients with normal (creatinine clearance [CrCl] 90 ml/min), mildly (60 to
90 ml/min), moderately (30 to 60 ml/min), and severely (30 ml/min) impaired CrCl (p
 0.001). Impaired renal function was associated with increased mortality after adjusting for
previously identified correlates of mortality (using Cr: odds ratio [OR] for mild impairment
1.52, 95% confidence interval [CI] 1.30 to 1.77, p  0.001; OR for severe impairment 3.73,
95% CI 2.55 to 5.45, p  0.001; using CrCl: OR for mild impairment 1.38, 95% CI 1.10 to
1.73, p  0.006; OR for moderate impairment 2.06, 95% CI 1.59 to 2.66, p  0.001; OR
for severe impairment 3.81, 95% CI 2.57 to 5.65, p  0.001).
CONCLUSIONS In the setting of STEMI, elevated Cr and/or impaired CrCl on presentation is associated
with increased mortality, independent of other conventional risk factors and TRS. This
association does not appear to be mediated by reduced fibrinolytic efficacy among patients
with impaired renal function or by the presence of congestive heart failure on
presentation. (J Am Coll Cardiol 2003;42:1535–43) © 2003 by the American College of
Cardiology Foundation
Previous studies have demonstrated that impaired renal
function is associated with poorer clinical outcomes in the
setting of unstable angina and non–ST-segment elevation
myocardial infarction (STEMI) and after a percutaneous
See page 1544
coronary intervention (PCI) as well as coronary artery
bypass graft surgery (1–8). The goal of the present study
was to extend these observations to examine the association
of baseline creatinine (Cr) and creatinine clearance (CrCl)
with subsequent clinical outcomes after fibrinolytic admin-
istration among patients with STEMI who received optimal
reperfusion therapy. We hypothesized that impaired renal
function (elevated Cr and impaired CrCl) would be associ-
ated with poorer clinical outcomes after fibrinolytic admin-
istration. We also sought to examine the relation between
Cr and CrCl with epicardial flow and myocardial perfusion.
METHODS
Clinical and angiographic data were pooled from the
Thrombolysis In Myocardial Infarction (TIMI) trial-10A,
-10B, and -14 trials. The TIMI-10A trial was a non-
randomized, open-label, dose-escalation study of eight as-
cending doses of tenecteplase, a mutant of recombinant
tissue plasminogen activator, in 113 patients (9). The
TIMI-10B trial was a randomized trial of 880 patients
comparing 30, 40, and 50 mg tenecteplase versus front-
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loaded recombinant tissue plasminogen activator (10). Data
from 1,187 patients enrolled in the TIMI-14 trial compar-
ing fibrinolytic versus abciximab plus a reduced dose fi-
brinolytic were also included (11,12). Angiography was
performed at 60, 75, and 90 min after thrombolytic admin-
istration (9–12). Nitroglycerin (intravenous or sublingual)
was administered every 15 min if the systolic blood pressure
(BP) exceeded 110 mm Hg (9–12). Clinical data were also
pooled from the Intravenous nPA for the Treatment of
Infarcting Myocardium Early (InTIME-II) trial, which
compared the thrombolytics n plasminogen activator versus
tissue-type plasminogen activator in 15,078 STEMI pa-
tients (13). The distribution of the TIMI risk score (TRS)
for STEMI, as previously reported (14), was used to assess
the association of Cr and CrCl with mortality in low-risk
(TRS 0 to 2), intermediate-risk (TRS 3 to 4), and high-risk
(TRS 5) patients. Creatinine clearance was divided into
four categories: normal (90 ml/min) and mildly (60 to
90 ml/min), moderately (30 to60 ml/min), and severely
impaired (30 ml/min), as defined by the Kidney Disease
Outcome Quality Initiative (15).
Angiographic analysis methods. Angiographic outcomes
were assessed at the TIMI Angiographic Core Laboratory
by a single observer (Dr. Gibson), who was blinded to the
clinical outcomes and drug assignment. The TIMI flow
grade (16), corrected TIMI frame count (CTFC) (17–20),
and TIMI myocardial perfusion grade (21) were assessed as
previously defined. The optimal single-plane projection was
selected that identified the stenosis in its greatest severity
with minimal foreshortening or overlapping of branches,
and end-diastolic frames were chosen for quantitative an-
giographic analysis (22).
Statistical analysis. All analyses were performed using
Stata version 7.0 (Stata Corp., College Station, Texas). All
continuous variables are reported as the mean  SD.
Analysis of variance was used for the analysis of continuous
variables. The non-parametric Kruskal-Wallis test was used
for the CTFC analysis when data were imputed to an
occluded vessel. The chi-square test was used for the
analysis of categorical variables. A test for trend across
ordered groups was performed for the three Cr groups and
four CrCl groups (Stata version 7.0). A multivariate logistic
regression model was used for the analysis of 30-day mortality,
adjusting for age, pulse, BP, history of congestive heart failure
(CHF), Killip class II to IV on presentation, gender, history of
diabetes, previous MI, history of hypertension, time to treat-
ment, and anterior myocardial infarction (MI). Kaplan-Meier
curves were generated for mortality through two years of
follow-up. The log-rank test was used to test the equality of the
Table 1. Baseline Characteristics by Creatinine Group
Normal
Cr <1.2 mg/dl
(n  12,377)
Mild Renal Impairment
Cr >1.2–2.0 mg/dl
(n  4,126)
Severe Renal Impairment
Cr >2.0 mg/dl
(n  207)
p Value
for Trend
Gender (% male) 71.8% 86.7% 75.9%  0.01
Age (yrs) 59.8  11.8 63.5  11.9 67.1  11.6  0.01
Race (% white) 93.1% 93.2% 86.5% 0.15
Weight (kg) 77.6  14.6 80.2  14.2 77.2  14.5  0.01
Cigarette smoking 48.5% 37.6% 30.2%  0.01
Previous MI 14.0% 20.3% 23.9%  0.01
History of diabetes 13.7% 14.2% 30.6%  0.01
History of CHF 2.1% 5.0% 14.2%  0.01
History of hypertension 28.7% 36.2% 58.1%  0.01
Previous PCI 4.7% 5.8% 5.3% 0.01
Previous CABG 2.4% 3.4% 5.7%  0.01
Admission SBP (mm Hg) 139.3  21.3 136.9  22.8 137.3  27.7  0.01
Admission DBP (mm Hg) 82.2  13.6 81.3  14.2 79.6  16.1  0.01
Admission pulse (per min) 75.7  17.3 76.3  19.6 79.6  22.4 0.15
Killip class II–IV 10.4% 16.4% 27.6%  0.01
Anterior MI 41.8% 40.3% 39.7% 0.08
Median time (h) from symptom onset to
treatment (IQ range)
2.9 (2.0–4.1) 2.75 (1.9–3.9) 3.45 (2.3–4.6)  0.01
Hypercholesterolemia* 24.7% 27.6% 33.3% 0.16
*Not collected in the Intravenous nPA for the Treatment of Infarcting Myocardium Early (InTIME-2) trial. Data are presented as the percentage of subjects or mean value 
SD, unless otherwise indicated.
CABG  coronary artery bypass graft surgery; CHF  congestive heart failure; Cr  creatinine; DBP  diastolic blood pressure; MI  myocardial infarction; PCI 
percutaneous coronary intervention; IQ  interquartile; SBP  systolic blood pressure.
Abbreviations and Acronyms
CHF  congestive heart failure
Cr(Cl)  creatinine (clearance)
CTFC  corrected TIMI frame count
ICH  intracranial hemorrhage
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
TRS  TIMI risk score
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survivor function across groups, and the test for trend of the
survivor function was performed across the ordered groups.
RESULTS
Baseline characteristics. There were 12,377 patients
(74.1%) with normal Cr (1.2 mg/dl), 4,126 patients
(24.7%) with mild renal impairment (Cr 1.2 to 2.0
mg/dl), and 207 patients (1.2%) with severe renal impair-
ment (Cr 2.0 mg/dl). Normal CrCl 90 ml/min was
present in 6,062 patients (36.4%), mild impairment (60 to
90 ml/min) in 6,795 patients (40.9%), moderate impair-
ment (30 to 60 ml/min) in 3,514 patients (21.2%), and
severe renal impairment or failure (30 ml/min) in 264
patients (1.6%).
There was a stepwise increase in co-morbidities among
patients with normal, mildly impaired, and severely im-
paired renal function (Tables 1 and 2). Patients with mildly
and severely impaired renal function were older, and the
frequency of previous MI, diabetes, CHF, hypertension,
and the incidence of previous coronary artery bypass graft
surgery was increased among these patients. Patients with
severe renal impairment were more often of a non-white
race. Cigarette smoking was less frequent among patients
with mild and severe renal impairment. At presentation,
patients with mildly or severely impaired renal function
were more often tachycardic and in Killip class II to IV
heart failure. The duration of symptoms before presentation
was longer among patients with severe renal impairment.
Angiographic findings (TIMI flow grade, TIMI frame
count, TIMI myocardial perfusion, minimum lumen diam-
eter, or percent diameter stenosis) after thrombolytic ad-
ministration in the TIMI-10A, -10B and -14 angiographic
trials were not associated with Cr or CrCl (Tables 3 and 4).
Clinical outcomes. There was a stepwise increase in mor-
tality among patients with normal, mildly, and severely
impaired renal function (p  0.0001 for each) and among
Table 2. Baseline Characteristics by CrCl Group
Normal
CrCl >90 ml/min
(n  6,062)
Mild Renal
Impairment
CrCl 60 to <90 ml/min
(n  6,795)
Moderate Renal
Impairment
CrCl 30 to <60 ml/min
(n  3,514)
Severe Renal
Impairment
CrCl <30 ml/min
(n  264)
p Value for
Trend
Gender (% male) 87.6% 77.1% 54.4% 39.8%  0.01
Age (yrs) 52.1  9.6 62.3  9.2 71.7  8.6 76.0  10.7  0.01
Race (% white) 92.5% 93.0% 94.3% 90.5% 0.014
Weight (kg) 87.2  14.3 76.2  11.0 67.8  11.4 62.6  14.1  0.01
Cigarette smoking 60.6% 42.5% 27.5% 21.0%  0.01
Previous MI 12.2% 16.2% 20.1% 24.0%  0.01
History of diabetes 13.8% 13.5% 15.1% 18.6% 0.03
History of CHF 1.2% 2.3% 5.9% 16.0%  0.01
History of hypertension 26.0% 30.3% 38.8% 52.5%  0.01
Previous PCI 5.2% 5.2% 4.1% 5.3% 0.06
Previous CABG 1.9% 3.0% 3.4% 4.1%  0.01
Admission SBP (mm Hg) 140.3  20.7 138.4  21.7 136.7  22.8 134.8  26.7  0.01
Admission DBP (mm Hg) 84.2  13.5 81.7  13.6 79.1  13.8 77.1  15.4  0.01
Admission pulse (per min) 76.3  16.8 75.0  17.7 76.4  19.9 80.6  23.3 0.23
Killip class II–IV 8.0% 11.2% 19.5% 26.4%  0.01
Anterior MI 39.9% 42.0% 42.8% 41.4%  0.01
Median time (h) from symptom onset
to treatment (IQ range)
2.8 (2–4) 2.8 (2–4) 3 (2.2–4.2) 3.6 (2.5–4.8)  0.01
Hypercholesterolemia* 25.6% 25.1% 26.0% 16.7% 0.83
*Not collected in InTIME-2. Data are presented as the percentage of subjects or mean value  SD, unless otherwise indicated.
CrCl  creatinine clearance; other abbreviations as in Table 1.
Table 3. Angiographic Characteristics by Creatinine Group*
Normal
Cr <1.2 mg/dl
(n  1,565)
Mild Renal
Impairment
Cr >1.2–2.0 mg/dl
(n  401)
Severe Renal
Impairment
Cr >2.0 mg/dl
(n  13)
p Value
for Trend
TFG 2/3 at 90 min (%) 81.0 (1,268/1,565) 80.1 (321/401) 100 (12/12) 0.89
Median CTFC at 90 min 35 (23–70.6) 35 (24–78) 29.5 (17.5–34) 0.83
(IQ range) (n  1,537) (n  390) (n  12)
TMPG 2/3 at 90 min (%) 35.1 (276/787) 32.0 (66/206) 45.5 (5/11) 0.68
Stenosis at 90 min (%) 70.9  19.5 (n  1,533) 72.7  17.2 (n  390) 65.8  9.15 (n  12) 0.44
MLD at 90 min (mm) 0.86  0.63 (n  532) 0.86  0.58 (n  390) 1.10  0.29 (n  12) 0.21
Thrombus present (%) 29.4 (458/1,560) 31.0 (123/397) 30.8 (4/13) 0.53
*TIMI-10A, TIMI-10B, and TIMI-14 only. Data are presented as the percentage of subjects, median value (interquartile [IQ] range), or mean value  SD.
Cr  creatinine; CTFC  corrected TIMI frame count; MLD  minimum lumen diameter; TFG  TIMI flow grade; TMPG  TIMI myocardial perfusion grade.
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patients with normal, mildly, moderately, and severely
impaired renal function by CrCl (p  0.001) (Fig. 1).
Kaplan-Meier curves show the mortality increased early
during the follow-up and continued to separate up to two
years of follow-up in the severely impaired renal function
group (p  0.001 for each) (Fig. 2). Within each TRS
category (0 to 2, 3 to 4, 5), there was a stepwise increase
in mortality among patients with normal, mildly, and
severely impaired renal function (p  0.0001 for each) (Fig.
3A) and among patients with normal, mildly, moderately,
and severely impaired renal function by CrCl (p  0.001)
(Fig. 3B). Heart failure as a cause of death increased with
increasing renal impairment: 24.6%, 35.9%, and 46.2% for
normal, mildly, and severely impaired Cr, respectively (p 
0.0001 for trend), and 23.9%, 27.4%, 29.8%, and 48.2% for
normal, mildly, moderately, and severely impaired CrCl,
respectively (p  0.0014 for trend).
In an analysis restricted to patients 65 years old, a
similar stepwise increase in mortality was observed as renal
impairment increased (Fig. 4). Both impaired Cr and CrCl
were related to mortality in a stepwise fashion when
stratified by the presence or absence of a history of CHF at
baseline (Figs. 5A and 5B) and Killip class I and Killip class
II to IV at presentation (Figs. 6A and 6B). Mildly and
severely impaired renal function were associated with in-
creased mortality in a multivariate model adjusting for age,
pulse, BP, history of CHF, Killip class II to IV on
presentation, gender, history of diabetes, previous MI,
history of hypertension, time to treatment, and anterior MI
(odds ratio [OR] for mild impairment 1.52, 95% confidence
interval [CI] 1.30 to 1.77; p  0.001; OR for severe
impairment 3.73, 95% CI 2.55 to 5.45; p  0.001).
Likewise, mildly, moderately, and severely impaired renal
function by CrCl was associated with increased mortality in
a multivariate model (OR for mild impairment 1.38, 95%
CI 1.10 to 1.73; p  0.006; OR for moderate impairment
2.06, 95% CI 1.59 to 2.66; p  0.001; OR for severe
impairment 3.81, 95% CI 2.57 to 5.65; p  0.001).
Intracranial hemorrhage (ICH) was associated with in-
creased renal impairment: 0.9%, 1.1%, and 2.9% for normal,
Table 4. Angiographic Characteristics by CrCl Group*
Normal
CrCl >90 ml/min
(n  890)
Mild Renal Impairment
CrCl 60 to <90 ml/min
(n  789)
Moderate Renal
Impairment
CrCl 30 to <60 ml/min
(n  269)
Severe Renal
Impairment
CrCl <30 ml/min
(n  16)
p Value
for Trend
TFG 2/3 at 90 min (%) 80.7 (718/890) 80.2 (633/789) 85.5 (230/269) 93.3 (14/15) 0.11
Median CTFC at 35.3 (23–75.9) 34.7 (24–785) 32.9 (24–50) 28.2 (18–34) 0.08
90 min (IQ range) (n  869) (n  775) (n  265) (n  15)
TMPG 2/3 at 90 min (%) 32.6 (141/433) 35.6 (142/397) 36.8 (56/152) 46.2 (6/13) 0.18
Stenosis at 90 min (%) 71.0  18.8 (n  871) 71.2  19.7 (n  774) 71.3  18.1 (n  263) 70.9  12.6 (n  15) 0.76
MLD at 90 min (mm) 0.89  0.65 (n  870) 0.84  0.59 (n  774) 0.84  0.59 (n  263) 0.91  0.37 (n  15) 0.16
Thrombus present (%) 31.5 (280/888) 29.9 (234/782) 20.8 (56/269) 31.3 (5/16)  0.01
*TIMI-10A, TIMI-10B, and TIMI-14 only. Data are presented as the percentage of subjects, median value (interquartile [IQ] range), or mean value  SD.
CrCl  creatinine clearance; other abbreviations as in Table 3.
Figure 1. Mortality at 30 days according to baseline creatinine (Cr) and creatinine clearance (CrCl). OR  odds ratio.
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Figure 3. Mortality at 30 days according to baseline (A) Cr and (B) CrCl stratified by TIMI risk score (TRS). Abbreviations as in Figure 1.
Figure 2. Kaplan-Meier survival curves through two years according to baseline Cr and CrCl. Data available through 30 days only in TIMI-10A and
TIMI-14. Abbreviations as in Figure 1.
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Figure 4. Mortality at 30 days according to baseline Cr stratified by TRS in patients over the age of 65 years. Abbreviations as in Figures 1 and 3.
Figure 5. Mortality at 30 days according to baseline (A) Cr and (B) CrCl stratified by history (Hx) of congestive heart failure (CHF) at presentation.
Abbreviations as in Figure 1.
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mildly, and severely impaired Cr, respectively (p 0.057 for
trend); and 0.6%, 0.8%, 1.8%, and 3.0% for normal, mildly,
moderately, and severely impaired CrCl, respectively (p 
0.0001 for trend). Although the CrCl group was not
significantly associated with ICH in a multivariate model
adjusting for known correlates of ICH (age, gender, systolic
and diastolic BP), severely impaired Cr tended to be
associated with increased ICH (multivariate OR for severe
impairment 2.31, 95% CI 0.99 to 5.37, p  0.053).
DISCUSSION
This study extends previous observations regarding the
association of renal dysfunction and adverse clinical out-
comes among patients with coronary artery disease. In the
presence of STEMI, elevated Cr and/or reduced CrCl on
presentation are associated with increased mortality, inde-
pendent of other conventional risk factors and TRS. Heart
failure as the primary cause of death increased with increas-
ing renal impairment. Retrospective analyses have demon-
strated that renal dysfunction is associated with an increased
risk of CHF and mortality after acute MI, and that while
reperfusion therapy may improve outcomes, reperfusion
therapy is less frequently administered to these patients
(23,24). Elderly patients with renal dysfunction are less
frequently treated with aspirin, beta-blockers, and fibrino-
lytic therapy, and they undergo angiography and angioplasty
less frequently during the index hospitalization (25).
In contrast to previous observational studies suggesting
lower rates of pharmacologic and interventional therapy
Figure 6. Mortality at 30 days according to baseline (A) Cr and (B) CrCl stratified by Killip class at presentation.
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among patients with renal insufficiency, all patients (regard-
less of baseline Cr or CrCl) received reperfusion therapy for
STEMI in the present study, including fibrinolytic and
aspirin therapy within 6 to 12 h of symptom onset in all
patients, beta-blocker therapy in a large proportion, and
early PCI in many patients. Despite the facts that aggressive
pharmacologic treatment was administered to all patients
and the epicardial and myocardial reperfusion rates were
equivalent, reduced renal function remained associated with
impaired survival through up to two years of follow-up. This
finding was also observed when the analysis was restricted to
patients over the age of 65 years.
Elevated Cr on presentation was associated with in-
creased ICH, independent of age, gender, and BP. Given
these findings of increased ICH with increased renal im-
pairment at presentation, physicians should exercise caution
in administering fibrinolytics to patients with increased Cr;
primary PCI may represent a favorable alternative therapy.
However, the risk of ICH in primary PCI patients present-
ing with renal impairment has not been defined, and
likewise may be associated with increased rates of ICH.
Because Cr levels were measured at presentation, which
was in general within 3 h of symptom onset, these Cr levels
likely reflect renal status near the time of onset of the event
and less likely reflect changes in renal hemodynamics due to
impaired systemic perfusion (26). Although other biomar-
kers reflect activation of inflammation (high-sensitivity
C-reactive protein, sCD40 ligand, interleukin-6), necrosis
(troponin, creatine kinase), the presence of a “metabolic
syndrome” (glycosylated hemoglobin, microalbuminuria), or
activation of the neuroendocrine system (brain natriuretic
peptide), it could be speculated that Cr and CrCl are
integrative markers of metabolic abnormalities, neuroendo-
crine activation, and end-organ damage due to several
cardiac risk factors, including hypertension, dyslipidemia,
diabetes, and vascular disease in general.
Study limitations. This analysis is a non-randomized,
retrospective analysis, and as such, it is possible that both
identified and unidentified confounders may have influ-
enced the outcomes. Strict enrollment criteria are used in
clinical trials, and the results observed herein may not be
applicable to all patients in clinical practice.
Conclusions. In the setting of STEMI, elevated Cr and/or
impaired CrCl on presentation is associated with increased
mortality, independent of other conventional risk factors
and TRS. This association does not appear to be mediated
by reduced fibrinolytic efficacy among patients with im-
paired renal function.
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